Login
Business
Entertainment
World
Health
Environment
Lifestyle
National
Science
Sports
World
Movies
Web Series
Technology
Cricket
Coronavirus
Auto
Ajab Ghazab
Finance
India
International
Religious
Politics
Home Articles Viatris
Biocon Biologics appoints Shreehas Tambe as MD, CEO \
2 min read
\
\

Biocon Biologics appoints Shreehas Tambe as MD, CEO

 06-Dec-2022
Tambe takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the board of Biocon Biologics.
06-Dec-2022 Business
\
Biocon Biologics completes acquisition of Viatris’ Global Biosimilars Business \
11 min read
\
\

Biocon Biologics completes acquisition of Viatris’ Global Biosimilars Business

 30-Nov-2022
Bengaluru (Karnataka) [India], November 30 (ANI/PRNewswire): Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS).
30-Nov-2022 Business
\
Biocon subsidiary completes acquisition of Viatris for USD 3 billion \
4 min read
\
\

Biocon subsidiary completes acquisition of Viatris for USD 3 billion

 29-Nov-2022
According to a statement by the pharma company, Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators including the US Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors, respectively.
29-Nov-2022 World
\
Biocon Biologics to acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in stock and cash \
4 min read
\
\

Biocon Biologics to acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in stock and cash

 01-Mar-2022
Bengaluru (Karnataka) [India], March 1 (ANI/PR Newswire): Biocon Biologics Ltd, a subsidiary of Biocon Ltd (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd (BBL) will acquire Viatris' biosimilars business to create a unique fully integrated global biosimilars enterprise.
01-Mar-2022 Business
\